The study on inducing fluconazole resistance in Candida albicans and the stability of induced resistance

Chinese Journal of Antibiotics

Volumn 29, Issue 6, 2004, Pages 374-377

  Han, Xu Dong ^a   Zhang, Yong Xin ^a   Zhang, Qiang Qiang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Candida albicans; Fluconazole; MIC; Resistance

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA ALBICANS; FUNGUS CULTURE; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 4043113417     PISSN: 10018689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Law D, Moore C B, Wardle H M, et al. High prevalence of antifungal resistance in Candida spp from patients with AIDS [J]. J Antimicrob Chemother,1994,34(5):659
2. Chavanet P, Lopez J, Grappin M, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients [J]. AIDS,1994,8(7):945
3. National committee for clinical laboratory standards. Referenced method for broth dilution antifungal susceptibility testing of yeasts [M]. Approved standard M27-A. Pennsylvania: NCCLs,1997,17(9):1
4. Pfalleir M A, Jones R N, Messer S A, et al. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program [J]. Diagn Microbiol Infect Dis,1998,31(1):327
5. Viudes A, Peman J, Canton E, et al. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death [J]. Eur J Clin Microbiol Infect Dis,2002,21(11):767
6. McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants [J]. Cochrane Database Syst Rev,2003,(1):CD00385
7. Bow E J, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials [J]. Cancer,2002,94(12):3230
8. Millon L, Manteaux A, Reboux G, et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype [J]. J Clin Microbiol, 1994,32(4):1115
9. Marr K A, Lyons C N, Ha K, et al. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans [J]. Antimicrob Agents Chemother,2001,45 (1):52
10. Marr K A, Lyons C N, Rustad T R, et al. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR [J]. Antimicrob Agents Chemother,1998,42(10):2584
11. Graybill J R, Najvar L K, Holmberg J D, et al. Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response [J]. Antimicrob Agents Chemother,1995,39(10):2197